Mounjaro is a highly effective, UK licensed weight loss treatment, shown in clinical trials to help achieve ~20% body weight loss. It is the latest GLP-1 weight loss injection, and is used for people with a body mass index (BMI) over 30, or those with a BMI of 28 and a weight-related medical condition.
It contains the drug Tirzepatide and is a registered trademark of Eli Lilly.
It is known as Zepbound in the US, but launched in the UK under the brand name Mounjaro.
It is used ONCE weekly, as a subcutaneous (under the skin) injection. More information on how to inject Mounjaro can be found in the Patient Information Leaflet.
This video gives information on Mounjaro, how it works, and what to expect during your treatment https://youtu.be/arT69UoLGjA.